Skip to main content

Itraconazole, Serum or Plasma

CPT 80189
Synonyms
  • Sporanox®

Test Details

Methodology

Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Result Turnaround Time

4 - 6 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

Treatment of susceptible fungal infections in immunocompromised and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis and onychomycosis of the toenail and fingernail. It has been recommended that routine monitoring occur during the first week of therapy to ensure therapeutic levels are achieved for each individual and to continue monitoring if clinical presentations do not improve or decline.

Limitations

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

Specimen Requirements

Specimen

Serum (preferred) or plasma

Volume

1 mL

Minimum Volume

0.5 mL

Container

Red-top tube or lavender-top (EDTA) tube

Collection Instructions

Transfer separated serum or plasma to a plastic transport tube. Do not use a gel barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage times, the decrease in drug level due to absorption may be clinically significant.

Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Storage Instructions

Refrigerate. Stable for 14 days at room temperature, refrigerated, or frozen.

Causes for Rejection

Gel barrier tubes

References

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162-1176.24379304
Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother. 2009 Jan;53(1):24-34.18955533
Clinical Primer: Potential Hepatic Complications With Triazole Therapy. Tinton Falls, NJ: Fallon Medica LLC; 2010.

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
700833 Itraconazole and Mtb, S/P 700283 Itraconazole ug/mL 10989-2
700833 Itraconazole and Mtb, S/P 700835 Hydroxyitraconazole ug/mL 18337-6
Order Code700833
Order Code NameItraconazole and Mtb, S/P
Order Loinc
Result Code700283
Result Code NameItraconazole
UofMug/mL
Result LOINC10989-2
Order Code700833
Order Code NameItraconazole and Mtb, S/P
Order Loinc
Result Code700835
Result Code NameHydroxyitraconazole
UofMug/mL
Result LOINC18337-6